Patent · US Active

Use of xenon for treating hypersensitivity to pain

US8632821B2 · kind B2 · utility

1Cited by

0References

7Claims

0Family size

Assignees

L'Air Liquide, Societe Anonyme Pour l'Etude et l'Exploitation des Procedes Georges Claude · FR
Universite de Bordeaux Segalen · FR

Inventors

Baptiste Bessiere · Issy-les-Moulineaux, FR
Guy Simonnet · Bordeaux, FR

Key dates

Filing date	Jul 13, 2010
Grant date	Jan 21, 2014
Priority date	—
Expiry date	Jul 13, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P29/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a gaseous mixture containing oxygen (O2) and a volume proportion of 20 to 70% of xenon (Xe) for use as an inhalable drug for preventing or treating hypersensitivity to pain in humans or animals, in particular hypersensitivity to pain expressed as hyperalgesia or allodynia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.